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253 The shape and relevance of the oral glucose tolerance test
(OGTT) curve in CF
D. Nazareth1, K. Mohan1, P. Browning2, M. Walshaw1. 1Liverpool Adult CF
Unit, Liverpool, United Kingdom; 2Liverpool Heart and Chest Hospital, Research
Laboratories, Liverpool, United Kingdom
Objectives: In normal individuals, the shape of the OGTT curve (monophasic or
biphasic) is inﬂuenced not only by the glucose load but also the patient’s metabolic
response. This has not been studied in CF and may give an insight into the abnormal
glucose handling even in those without CFRD.
Method: We compared the area under the curve (AUC) for glucose, insulin,
C-Peptide and glucagon following a 2-hour OGTT in 13 pancreatic insufﬁcient
adult CF (without known CFRD) and 10 healthy subjects, classiﬁed according to
the OGTT curve shape.
Results: See table. Biphasic curves were more common in CF (Chi2 = 4.97,
p< 0.03), and these patients also had higher glucagon levels (p = 0.01) compared to
their healthy counterparts, whilst CF patients with monophasic curves had reduced
C-peptide levels (p = 0.04).
Conclusions: This study shows that the shape of the OGTT curve in CF is related
to pancreatic alpha and beta-cell function, as well as glucose load. The OGTT shape
index may be a useful screening tool to make an early diagnosis of diabetes in CF.
Table: OGTT curve shape
Controls CF
Monophasic
(n = 7)
Biphasic
(n = 3)
p Monophasic
(n = 2)
Biphasic
(n = 11)
p
AUCglucose (mmol/L) 605 (107) 851 (137) 0.009 590 (40) 935 (135) 0.005
AUCinsulin (mU/ml) 4394 (1864) 5502 (1379) 0.85 2537 (1965) 3962 (1543) 0.48
AUCC−Peptide (ng/ml) 1017 (242) 1146 (258) 0.41 493 (291) 974 (421) 0.19
AUCglucagon (pg/ml) 7782 (1408) 6373 (182) 0.06 8967 (1608) 7868 (1678) 0.56
Results are mean (SD).
Reference(s)
Diabetes Care 2003 Apr; 26(4): 1026−33.
254 The prognostic signiﬁcance of hypoglycaemia on oral glucose
tolerance tests in adults with cystic ﬁbrosis (CF): A prospective
clinical study
M.J. Harrison1,2, K.J. Neff1,3, C. Shortt1, C. Fleming1, M. Mccarthy1,
S.M. O’Riordan4, D.M. Murphy1,2, D.J. O’Halloran3, B.J. Plant1,2. 1Cork Adult
Cystic Fibrosis Centre, Cork University Hospital, Dept of Respiratory Medicine,
Cork, Ireland; 2HRB Clinical Research Facility, University College Cork, Cork,
Ireland; 3Department of Endocrinology and Metabolism, Cork University Hospital,
Cork, Ireland; 4Dept. of Paediatrics, Cork University Hospital, Cork, Ireland
Objectives: Current guidelines recommend an annual oral 75 g glucose tolerance
test (OGTT) to screen for Cystic Fibrosis-Related Diabetes (CFRD). Hypoglycaemia
during an OGTT is common, but the relevance of this phenomenon is unclear. This
study aims to determine the prognostic signiﬁcance associated with hypoglycaemia
on OGTT with regards to CFRD and clinical outcomes.
Methods: Patients attending the Cork Adult CF Centre were recruited over a one-
year period during 2006/07, and were followed for ﬁve years with annual OGTT
and pulmonary function testing.
Conclusion: 76 participants were included. The mean age was 26±8 years. 54
(62%) of the cohort were male. 48 (63%) had normal glucose tolerance on OGTT
at entry. A further 12 (16%) had impaired fasting glucose (IFG) or impaired glucose
tolerance (IGT), and 16 (21%) had hypoglycaemia on OGTT. The hypoglycaemic
cohort had a lower rate of progression to CFRD over 5 years as compared to the
normal OGTT group (6% vs 28%, p< 0.001), and had a higher rate of pancreatic
insufﬁciency (PI) (87% vs 77%, p< 0.001). They had a signiﬁcantly greater FEV1
on entry to the study than the IFG/IGT group (74±17 vs 59±22% predicted,
p = 0.04) and the difference in FEV1 persisted over the ﬁve-year follow-up (79±16
vs 59±21% predicted, p = 0.003).
This study highlights that hypoglycaemia on OGTT may be associated with a lower
risk of progression to CFRD in adult CF. Hypoglycaemia on OGTT is associated
with PI when compared to those with a normal OGTT, and a higher FEV1 when
compared to those with IFG/IGT. Further studies are required to determine the
mechanism of hypoglycaemia, and its potential role as a prognostic indicator in CF.
255 Screening glucose disorders in cystic ﬁbrosis: Continuous
subcutaneous glucose monitoring compared to oral glucose
tolerance test
M. Santalha1, T.F. Barbosa2, B. Amaral2, T. Borges2, L. Ribeiro2, A.P. Silva2,
C. Cardoso2, M.J. Oliveira2, H. Cardoso2, V. Senra2, R. Herculano2. 1Centro
Hospitalar do Alto Ave, Guimara˜es, Portugal; 2Centro Hospitalar do Porto, Porto,
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Introduction: Diabetes is an important complication of cystic ﬁbrosis (CF). It is
associated with increased morbidity and, if left untreated, can lead to deterioration
of nutritional and pulmonary status.
Objectives and Methods: The aim of this study was to evaluate the glycemic
proﬁle with continuous glucose monitoring system (CGMS) in patients with CF
followed in a terciary pediatric center, and compare these results with oral glucose
tolerance test (OGTT) and HbA1c. Patients younger than 10 years, with current
corticosteroids or immunosuppressive treatment, those who were transplanted or
who already had the diagnosis of diabetes were excluded.
Results: Nine patients were included, ﬁve males, with a mean age of 17.8 years.
Three patients had homozygous DF508 CF-mutation. All patients had normal OGTT
and a median HbA1c value of 5.4±0.29% [5.1−5.9%]. Mean CGMS glucose was
102.7±8.2mg/dl and mean glucose lowest and highest values were 63.2±13.7mg/dl
[47−87mg/dl] and 164.5±27mg/dl [132–218mg/dl], respectively. In seven patients
CGMS showed peaks of glucose higher than 140mg/dl at least once after a meal
and one individual had values above 200mg/dl despite normal OGTT. We also
found asymptomatic hypoglycemias in ﬁve patients during CGMS
Conclusion: Most patients had a glucose proﬁle during CGMS with values below
200mg/dl. However, we observed abnormal glucose values in more than half of the
patients. Asymptomatic hypoglycemias found in this study may reﬂect an inadequate
insulin secretion.
The authors believe that CGMS allows a better diagnosis of glucose disorders in
patients with CF compared to OGTT.
256 The diagnostic utility of continuous glucose monitoring (CGM) in
cystic ﬁbrosis related diabetes (CFRD)
P. Dyce1, V. Malone1, D. Nazareth1, M. Walshaw1. 1Liverpool Adult CF Unit,
Liverpool, United Kingdom
The oral glucose tolerance test (OGTT) deﬁnes diabetes based on glucose thresholds
derived from a non-CF population to prevent micro-vascular complications and
may mislead in CF, where glucose handling is variable and clinical deterioration
is associated with lower levels of hyperglycaemia. CGM, validated for use in CF,
allows the evaluation of a glycaemic proﬁle, and is a stronger predictor for the
development of CFRD than an OGTT. To look at this further, we explored the
utility of CGM in CFRD diagnosis and management at our large adult CF centre
(n = 282; 40% CFRD) in 40 patients over 20 months, comparing it with changes in
weight, pulmonary function, HBA1C and antibiotic treatment. Food and exercise
diaries completed during CGM were also evaluated.
The results are summarised in the table. 55% were diagnosed with CFRD (glucose
7.8mmol/L >4.5% of the time) despite previous normal HBA1C and serial
glucose monitoring. Following insulin therapy, weight improved in 77%, lung
function in 50%, HBA1C in 56%; 64% required less IV antibiotic therapy and
55% fewer oral antibiotics.
Food and exercise diaries were interrogated and adjustments were made for 83%
of the group not commenced on insulin and 59% of the insulin commenced group.
This study demonstrates the utility of CGM as a diagnostic tool, especially since
HBA1C, OGTT and serial glucose monitoring have signiﬁcant limitations. The
guidance for the diagnosis of CFRD should be updated to include this more
physiological test.
Group FEV1
(%) [SD]
Weight
(kg) [SD]
HbA1C (IFCC
mmol/mol) [SD]
Pre Post Pre Post Pre Post
Insulin therapy (n = 22) 59 [24] 62 [25] 55 [8] 56 [8] 41 [4] 40 [4]
Dietary advice only (n = 18) 72 [18] 74 [17] 68 [18] 68 [19] 37 [6] 38 [4]
